Navigation Links
UCLA researchers design nanomachine that kills cancer cells
Date:4/1/2008

Researchers from the Nano Machine Center at the California NanoSystems Institute at UCLA have developed a novel type of nanomachine that can capture and store anticancer drugs inside tiny pores and release them into cancer cells in response to light.

Known as a "nanoimpeller," the device is the first light-powered nanomachine that operates inside a living cell, a development that has strong implications for cancer treatment.

UCLA researchers reported the synthesis and operation of nanoparticles containing nanoimpellers that can deliver anticancer drugs March 31 in the online edition of the nanoscience journal Small.

The study was conducted jointly by Jeffrey Zink, UCLA professor of chemistry and biochemistry, and Fuyu Tamanoi, UCLA professor of microbiology, immunology and molecular genetics and director of the signal transduction and therapeutics program at UCLA's Jonsson Comprehensive Cancer Center. Tamanoi and Zink are two of the co-directors for the Nano Machine Center for Targeted Delivery and On-Demand Release at the California NanoSystems Institute.

Nanomechanical systems designed to trap and release molecules from pores in response to a stimulus have been the subject of intensive investigation, in large part for their potential applications in precise drug delivery. Nanomaterials suitable for this type of operation must consist of both an appropriate container and a photo-activated moving component.

To achieve this, the UCLA researchers used mesoporous silica nanoparticles and coated the interiors of the pores with azobenzene, a chemical that can oscillate between two different conformations upon light exposure. Operation of the nanoimpeller was demonstrated using a variety of human cancer cells, including colon and pancreatic cancer cells. The nanoparticles were given to human cancer cells in vitro and taken up in the dark. When light was directed at the particles, the nanoimpeller mechanism
'/>"/>

Contact: Jennifer Marcus
jmarcus@cnsi.ucla.edu
310-267-4839
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Researchers study why high school boys dodge Phys Ed
2. Researchers Successfully Test Ebola Vaccines
3. Researchers identify a gene responsible for cases of Lou Gehrigs disease
4. Researchers identify a gene responsible for Lou Gehrigs disease
5. UCLA researchers examine human embryonic stem cell genome
6. Researchers Create Protective Sac for Growing Stem Cells
7. UC Irvine researchers present latest findings at emergency medicine forum
8. Researchers urge ethics guidelines for human-genome research
9. OHSU Cancer Institute researchers identify new approach to help control drug resistance in leukemia
10. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
11. Researchers Gain Insights Into On-Off Switch for Cells
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 1Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 4Natural born divers and the molecular traces of evolution 9035 1Natural born divers and the molecular traces of evolution 9035 2Reading the brain without poking it 9033 1Reading the brain without poking it 9033 2Reading the brain without poking it 9033 3Reading the brain without poking it 9033 4Reading the brain without poking it 9033 5